In agreement with a previous report on HFD-induced NAFLD animal model14, we demonstrated here that PON2 activity is inhibited in a PA-induced in vitro fatty liver model, whereas its expression level is not affected. Here, PON2 is linked to metabolic dysfunction-associated steatotic liver disease.